The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma

Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).

(2017) J. L. Wolf et al.   JOURNAL OF CLINICAL ONCOLOGY

Autophagy in Multiple Myeloma: What Makes You Stronger Can Also Kill You

(2013) Richard G. Carroll et al.   CANCER CELL

Control of Autophagic Cell Death by Caspase-10 in Multiple Myeloma

(2013) Laurence Lamy et al.   CANCER CELL

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

(2012) Grit Hutter et al.   ANNALS OF HEMATOLOGY

Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors

(2012) Michael R. Mattern et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis

(2012) M de Martino et al.   BRITISH JOURNAL OF CANCER

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma

(2012) Yadan Wang et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1

(2011) Rong Zeng et al.   ACTA PHARMACOLOGICA SINICA

Targeting Autophagy Augments In Vitro and In Vivo Antimyeloma Activity of DNA-Damaging Chemotherapy

(2011) Y. Pan et al.   CLINICAL CANCER RESEARCH

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

(2011) Pádraig D'Arcy et al.   NATURE MEDICINE

Dissection of the assembly pathway of the proteasome lid in Saccharomyces cerevisiae

(2010) Keisuke Fukunaga et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

(2010) F. van Rhee et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

(2010) G. W. Xu et al.   BLOOD

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Multiple Assembly Chaperones Govern Biogenesis of the Proteasome Regulatory Particle Base

(2009) Minoru Funakoshi et al.   CELL

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Effect of autophagy on multiple myeloma cell viability

(2009) B. Hoang et al.   MOLECULAR CANCER THERAPEUTICS

CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells

(2009) Silvia Masciarelli et al.   MOLECULAR IMMUNOLOGY

Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways

(2009) Brenda A. Schulman et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Some assembly required: dedicated chaperones in eukaryotic proteasome biogenesis

(2008) Andrew R. Kusmierczyk et al.   BIOLOGICAL CHEMISTRY

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Autophagy-mediated clearance of aggresomes is not a universal phenomenon

(2008) Esther S.P. Wong et al.   HUMAN MOLECULAR GENETICS

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

(2008) Kirsten Neubert et al.   NATURE MEDICINE

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome-Wide and Functional Annotation of Human E3 Ubiquitin Ligases Identifies MULAN, a Mitochondrial E3 that Regulates the Organelle's Dynamics and Signaling

(2008) Wei Li et al.   PLoS One